Skip to main content
. 2022 Sep 12;14(18):4427. doi: 10.3390/cancers14184427

Figure 4.

Figure 4

Overall survival rate (OS) of stage II/III gastric cancer (GC) patients according to the combination of survival risk stratification marker expression. A combination of inhibin subunit beta A (INHBA), matrix metallopeptidase-11 (MMP11), platelet-derived growth factor receptor-beta (PDGFRB), and galectin-10 (a), and a combination of secreted protein acidic and rich in cysteine (SPARC), INHBA, MMP11, and galectin-10 (b) are shown.